Intellia Therapeutics, Inc. (NTLA)
Uses CRISPR gene editing to develop cures for genetic diseases and cancer.
$10.38-0.03%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-9.7%
The outlook
NTLA is trading near the lower end of its 52-week range and below both its 50- and 200-day moving averages, signaling a downtrend. Analysts lean bullish with a "buy" consensus, and the average price target sits roughly 152% above the current price. The stock shows technical weakness despite optimistic analyst sentiment.
What’s behind the score
Analyst consensusBuy — 2.3 avg of 18 analysts
Price trendBelow its 50- & 200-day averages
52-week range12% of the way from its 52-week low to high
Price targetAvg target +152% vs current price
Analyst price target
~12-month · 18 analysts$26.17average target+152.1% vs now
Now $10.38
Low $8.00High $95.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.45B
52-wk high
$28.25
52-wk low
$7.95
50-day avg
$13.84
200-day avg
$13.35
Trailing P/E
—